Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerchemotherapycellsadjuvantradiotherapy
  Phrases that lowered it: multiplebmisclerosiskgbetween 18
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 4.9% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 69 (lowers risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Drug's FAERS reports with a death: 6.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 61.0% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, dermatology: Yes (raises risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Maximum age: 75 (lowers risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 81 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients NCT01355523 · started 2011 · scored riskier than 33% of active trials terminated
• Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy NCT02332928 · started 2015 · scored riskier than 75% of active trials terminated
• Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer NCT00925899 · started 2009 · scored riskier than 16% of active trials completed
• Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy NCT01091974 · started 2008 · scored riskier than 61% of active trials completed
• Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer NCT03716583 · started 2019 · scored riskier than 36% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.